Markets

Moderna Vaccinates First Patients In Its Phase 1 Clinical Trial Of mRNA-1469 To Treat Bundibugyo Ebolavirus Following Health Canada Approval

Aug 4, 2026 · 11:02 AM ET· updated 2h ago

Moderna, Inc. (NASDAQ:MRNA) today announced that following Health Canada's authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, the

Why It Matters

Moderna started testing a new vaccine for a rare disease after getting permission from Canada's health authority. This shows the company is working on different medicines, which is normal for big drug makers and something to watch as they report results.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MRNA57.62

+2.48 (+4.49%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.